TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03840252

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 3D gait analysis
Description: Computed analysis of posture and gait pattern and motor performance by kinematic and kinetics parameters analysis such as the step length, gait velocity, stride time variability, 3D joint kinematics, ground reaction forces, joint kinetics

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 3D gait analysis
Description: Computed analysis of posture and gait pattern and motor performance by kinematic and kinetics parameters analysis such as the step length, gait velocity, stride time variability, 3D joint kinematics, ground reaction forces, joint kinetics

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 3D gait analysis
Description: Computed analysis of posture and gait pattern and motor performance by kinematic and kinetics parameters analysis such as the step length, gait velocity, stride time variability, 3D joint kinematics, ground reaction forces, joint kinetics

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: rsfMRI
Description: MR scans acquired by 1.5 Tesla (Siemens Medical Systems, Erlangen, Germany).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: rsfMRI
Description: MR scans acquired by 1.5 Tesla (Siemens Medical Systems, Erlangen, Germany).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: rsfMRI
Description: MR scans acquired by 1.5 Tesla (Siemens Medical Systems, Erlangen, Germany).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Montreal Cognitive assesment (MoCA)
Description: Standard clinical questionnaire

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Montreal Cognitive assesment (MoCA)
Description: Standard clinical questionnaire

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Montreal Cognitive assesment (MoCA)
Description: Standard clinical questionnaire
Study: NCT00426010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: caffeine/placebo
Description: caffeine or placebo, either overt or covert

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: caffeine/placebo
Description: caffeine or placebo, either overt or covert

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: caffeine/placebo
Description: caffeine or placebo, either overt or covert

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: caffeine/placebo
Description: caffeine or placebo, either overt or covert
Study: NCT01264549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Procalcitonin assay - B.R.A.H.M.S PCT ultrasensitive Kryptor
Description: The physician will be given access to a PCT value for Day 1 - 7. Depending on the PCT concentrations, the protocol recommends or discourages from the use of antibiotics
Study: NCT03986450

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced recovery after surge(ERAS) protocol
Description: The components of ERAS multidisciplinary pathway concerning preoperative, operative, and postoperative period are as follows:~1. Preoperative care:~   Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis~2. Perioperative care:~Use of short-acting anesthetic agents Application of midthoracic, epidural anesthesia/analgesia Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia~Postoperative care:~Application of midthoracic, epidural anesthesia/analgesia Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization
Study: NCT02794259

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-tDCS
Study: NCT02243293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet
Study: NCT01853709

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fiber free diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fiber free diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Adjuvants

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol (PEG)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl
Study: NCT01706484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNO 1016
Description: comparison of different dosages of drug and placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNO 1016
Description: comparison of different dosages of drug and placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BNO 1016
Description: comparison of different dosages of drug and placebo
Study: NCT02483364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HC-SVT-1001(initial protocol); HC-SVT-1002 (protocol amendment)
Description: A single application in the context of a single surgical intervention.
Study: NCT03186638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02550314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fiblast,gelatin sponge,fibrin glue
Study: NCT03444818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-E6007
Description: Oral administration
Study: NCT01259128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER120 Nasal Spray 500 ng/day
Description: SER120 Level 1
Study: NCT03311893

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: natural orifice surgery
Description: evaluation of the awareness of the use of transvaginal, transoral and transcranial approach in surgical excision and the difference between the health staff and the pathology
Study: NCT03216213

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frame
Description: Vignette is framed in a way that nudges participant to leave a legacy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frame
Description: Vignette is framed in a way that nudges participant to leave a legacy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Norms
Description: Vignette informs the participant that most people choose an option to try to nudge participant into choosing that option as well
Study: NCT01259128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER120 nasal spray 750 ng/day
Description: SER120 (750 ng/day)
Study: NCT02981017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Porcine Intestinal submucosal xenograft
Description: Cook Biodesign ENT repair graft will be used in the experimental group to cover exposed bone in the sinonasal cavity as a result of the Draf III/endoscopic modified lothrop procedure.
Study: NCT03711110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive cardiovascular monitoring
Description: Schedule of visits: Evaluation before starting chemotherapy, at three and six months and annually for five years (eight visits: baseline, 3rd and 6th month, 1st, 2nd, 3rd, 4th and 5th years).~Assessment protocol: Anamnesis and physical examination; EKG; Echocardiogram; Biomarkers (troponin and natriuretic peptide); Structured counselling on healthy cardiac practices; Treatment optimization of cardiovascular risk factors and heart diseases; Quality of life (ECOG Performance status and Minnesota questionnaires); Interaction and management of patient care by the cardio-onco-hematology team. Moreover, cardiac MRI in centers participating in the CARTIER-MR sub-study.

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: Schedule of visits: Evaluation before starting chemotherapy, at three and six months and annually for five years (eight visits: baseline, 3rd and 6th month, 1st, 2nd, 3rd, 4th and 5th years).~Assessment protocol: Anamnesis and physical examination; ECOG Performance status; cardiac patient care based on the onco-hematologist criteria
Study: NCT04351685

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VPM1002
Description: The active ingredient of the recombinant BCG vaccine, VPM1002 is Mycobacterium bovis A dose of 0.05 ml will be administered intradermally.~Manufactured by the Serum Institute of India Pvt. Ltd., India~Diluent: 1 ml of Water for injection/vial

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG SII
Description: Commercially available BCG vaccine from Serum Institute of India Pvt. Ltd. A dose of 0.05 ml will be administered intradermally.~Manufactured by the Serum Institute of India Pvt. Ltd., India~Diluent: 1 ml of Sodium Chloride for injection/vial Injection
Study: NCT03216213

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Norms
Description: Vignette informs the participant that most people choose an option to try to nudge participant into choosing that option as well
Study: NCT04447209

Intervention type: OTHER
Intervention: Dietary counselling on Food Groups according to IYC Feeding practices, WHO
Description: Monitoring of Dietary diversity and growth

Intervention type: OTHER
Intervention: Dietary counselling on Food Groups according to IYC Feeding practices, WHO
Description: Monitoring of Dietary diversity and growth
Study: NCT01721434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar coloured placebo
Study: NCT03960398

Intervention type: DRUG
Intervention: Iatrogenic disease impact on emergency consultations
Description: Determination of the proportion of emergency consultations linked to iatrogenic diseases
Study: NCT04181255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curosurf
Description: This arm will consist of a single dose of Curosurf (200 mg/kg) that will be given in the Pediatric Cardiothoracic Unit (PCTU) after surgery once the subject has reached a normalized body temperature.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Description: This arm will consist of a single dose of sham (air) that will be given through the endotracheal tube in the Pediatric Cardiothoracic Intensive Care Unit after surgery once the subject has reached a normalized body temperature.
Study: NCT00749749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant)
Description: The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride
Study: NCT02730442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318
Description: Administration of F901318 intravenously
Study: NCT00749749

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ON-Q PainBuster Post-op Pain relief System
Description: 5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL \[900 mg\])
Study: NCT02138006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment
Description: Mealtime insulin (Actrapid) Basal insulin (Monotard)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard insulin treatment
Description: Insulin Mixtard
Study: NCT04022616

Intervention type: OTHER
Intervention: Specimen collection
Description: Specimens are obtained from patients who are being treated for breast malignancies.

Intervention type: OTHER
Intervention: Specimen collection
Description: Specimens are obtained from patients who are being treated for breast malignancies.

Intervention type: OTHER
Intervention: Specimen collection
Description: Specimens are obtained from patients who are being treated for breast malignancies.

Intervention type: OTHER
Intervention: Specimen collection
Description: Specimens are obtained from patients who are being treated for breast malignancies.
Study: NCT02229019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volunteer mealtime assistance
Study: NCT03593213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine capsules, oral administration, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine capsules, oral administration, once daily.
Study: NCT02730442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Oral administration
Study: NCT00028561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00118729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X Aqueous Nasal Spray
Study: NCT02243293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (RBV)
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (RBV)
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (RBV)
Description: Tablet
Study: NCT02208219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music-supported Therapy
Description: A Music-supported Therapy training will be provided to participants in the hospital during 4 weeks (5 sessions per week, 30 min per session). In this treatment, two different musical instruments will be used: a MIDI-piano and an electronic drum set to train fine and gross movements of the affected hand, respectively. Exercises will follow a modular therapy regime with stepwise increase of complexity in the number of tones to perform, velocity, order of playing, and fingers used for playing. Each exercise will be first played by the experimenter and will be subsequently repeated by the patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home-based Music-supported Therapy
Description: A Music-supported Therapy training at home will be provided to participants during 4 weeks (5 sessions per week, 30 min per session). Patients will play a portable roll-up MIDI-piano at home connected to the Synthesia LLC software. This software displays visual stimuli across a virtual piano on the computer screen which are served as cues to press the correct piano keys. A modular regime with stepwise increase in difficulty will be set in the program. With the aim to reinforce the training and solve problems that could appear at home, once per week patients will carry out the MST session in the hospital with the therapist. During this visit, each patient will complement his/her training with the electronic drum set and in order to train gross movements.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: This intervention comprises intensive training of the affected upper extremity during 4 weeks (5 sessions per week, 30 min per session). The conventional therapy program corresponds to standard therapies, prescribed by attending neurologists and adapted to the needs of every individual patient. Patients will receive intensive training on fine and gross movements of the affected upper extremity. A physical and occupational therapist will provide multiple exercises from the following options:~* Passive mobilization: controlled manipulation of movements to release a joint.~* Stretch and progressive resistance training.~* Task-specific training: reaching and manipulation of different objects.~* Intense physical training: repetition of sequence of movements.
Study: NCT02896946

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted nuclear magnetic resonance imaging
Description: All MRI examinations will be carried out using a Siemens Magnetom Avanto syngo MR B15 1.5 Tesla (Erlangen, Germany) or a Philips Intera 1.5 Tesla (Eindhoven, The Netherlands) and will include the following sequences: (i) T2 fat sat, with a FOV of 350 x 262, and a matrix of 384 x 207; slices, 30 per sequence, 6 mm thick; (ii) T1 in-phase and out-of-phase with a FOV of 380 x 262, and a matrix of 256 x 158; slices, 30 per sequence, 6 mm thick; (iii) T1 water excitation (= T1 ProSat), with a FOV of 300 x 300, and a matrix of 320 x 220; obtaining 20 slices of 4 mm; (iv) VIBE and THRIVE (dynamic T1 axial 3D EG after injection, during the arterial, portal venous, and late phases, in an axial plane, and optionally in a coronal plane during the portal venous phase), with a FOV of 400 x 312, a matrix of 384 x 192, and with fat suppression and breath-hold; slices 3 mm thick, with liver and pancreatic coverage. Contrast agent: gadobenate dimeglumine (MultiHance, Bracco Imaging, France).
Study: NCT02838667

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care plus Nephrology Care
Study: NCT01766102

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-operative Mammography
Description: The patient's breast specimen will be imaged in the operating room in an intra-operative imaging device - Biovision SN #30042
Study: NCT01320111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel and Sorafenib
Description: intravenous solution, 80 mg/sqm, 3 times per cycle, with one cycle = 28 d and application at days 1, 8 and 15~AND~pills (200mg), cycle 1: 400 mg / day cycle 2: 600 mg / day from cycle 3: 800 mg / day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: intravenous solution, 80 mg/sqm, 3 times per cycle, with one cycle = 28 d and application at days 1, 8 and 15
Study: NCT02243293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (RBV)
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493/ABT-530
Description: Tablet; ABT-493 co-formulated ABT-530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493/ABT-530
Description: Tablet; ABT-493 co-formulated ABT-530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493/ABT-530
Description: Tablet; ABT-493 co-formulated ABT-530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493/ABT-530
Description: Tablet; ABT-493 co-formulated ABT-530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493/ABT-530
Description: Tablet; ABT-493 co-formulated ABT-530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493/ABT-530
Description: Tablet; ABT-493 co-formulated ABT-530
Study: NCT03794791

Intervention type: BEHAVIORAL
Intervention: education
Description: Education Methods including video playing of HCV Introduction (disease profile, risk factors for infection, outcomes, HBV/HCV coinfection, reinfection, etc) for 5 min, booklets of relative information distribution, physicians and nurses consulting in clinic.

Intervention type: BEHAVIORAL
Intervention: no education
Description: Education Methods including video playing of HCV Introduction (disease profile, risk factors for infection, outcomes, HBV/HCV coinfection, reinfection, etc) for 5 min, booklets of relative information distribution, physicians and nurses consulting in clinic.
Study: NCT04660955

Intervention type: OTHER
Intervention: No Intervention - Observational study with MRI
Description: 90 minute MRI of the knees

Intervention type: OTHER
Intervention: No Intervention - Observational study with MRI
Description: 90 minute MRI of the knees
Study: NCT01675024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine, Period 1
Description: Formulation: transdermal~Dosage: 2 mg / 24 hours once at Day 2~Frequency: once every 24 hours~Duration: from Day 1 to Day 3
Study: NCT01766102

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Mammography
Description: There is not an added device associated with this arm.
Study: NCT01819740

Intervention type: OTHER
Intervention: determine the levels of the HEM substance in seminal plasma
Study: NCT01697709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Quetiapine pharmacotherapy for cannabis dependence

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules